POZEN, Inc. (NASDAQ:POZN)

rwh999 (< 20) Submitted: 3/12/2008 1:20:53 AM : Start Price: $10.29 POZN Score: -36.27

Will the FDA make POZN shine? Third times a charm.

steelpoker (22.85) Submitted: 2/22/2008 4:39:56 PM : Start Price: $12.29 POZN Score: -45.11

Product will be FDA approved... = blockbuster.

boater9384 (< 20) Submitted: 1/29/2008 8:26:07 PM : Start Price: $12.13 POZN Score: -44.33

Check out Zack's calling this the stock of the week.

bcvbrent (24.09) Submitted: 10/24/2007 9:56:34 AM : Start Price: $9.45 POZN Score: -18.04

Products will be brought to market.

tcampbellla (< 20) Submitted: 9/10/2007 3:40:42 AM : Start Price: $12.80 POZN Score: +40.69

The P/E Ratio is 240 for crying out loud!!!

ANALISISCOUNTS (88.04) Submitted: 9/7/2007 8:52:24 PM : Start Price: $12.80 POZN Score: +40.69

Got burnt (as many did) on this puppy only a little more than 1 month ago, when all indications pointed to it's migraine headache approval...Just the combination of 2 already accepted, frequently used over-the-counter drugs, right? BIG TIME WRONG!

Learned my lesson that FDA approval is incredibly difficult, as is the road ahead for this latest venture.

Just because a big pharma co. is tossing big bucks for a trial to be COMPLETED IN 2009, isn't worth the bumps-the-road along the way.

More food for SHORTS, as was the case Friday, when there were no shares available!

Up 28% on the start of a Phase III Trial? Gimme a break...wise-up!

tenmiles (99.97) Submitted: 8/1/2007 2:57:01 PM : Start Price: $17.11 POZN Score: -55.62

Expect Trexima to be approved - riskly play but $billion market potential.

Bartoman (49.83) Submitted: 7/14/2007 1:30:12 PM : Start Price: $18.74 POZN Score: -52.69

There is a real need for this type of medication and better yet therapy.

stockscreener (55.64) Submitted: 6/29/2007 4:52:42 PM : Start Price: $18.14 POZN Score: -53.91

Positive earning surprise > 36% past Q
Est. EPS > 700% next Q
120% better than S&P last 52 wks.
6 upgrades within 90 days

JimAnt (32.96) Submitted: 4/26/2007 11:50:23 AM : Start Price: $15.50 POZN Score: +48.66

Long-term underperform. Poorly managed. Obscenely high P/E at 241.29. Don't believe everything you hear on TV.

bananaball (< 20) Submitted: 4/26/2007 8:46:20 AM : Start Price: $15.50 POZN Score: -48.65

good looking opportunity

vizilite (57.86) Submitted: 3/9/2007 5:10:47 PM : Start Price: $14.87 POZN Score: -53.18

big drug targets

juicethewinner (22.23) Submitted: 2/15/2007 6:33:34 PM : Start Price: $16.79 POZN Score: -55.07

FDA approval of it's new drug is key, should get settled this year.

NewbieMcNewbers (< 20) Submitted: 1/19/2007 3:28:22 PM : Start Price: $17.06 POZN Score: +57.41

Just wondering what could justify a P/E that high. Anybody? Throw me a bone here.